Insight Molecular Diagnostics (IMDX) Depreciation & Amortization (CF) (2015 - 2026)

Insight Molecular Diagnostics has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $631000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 30.37% year-over-year to $631000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 43.53% YoY) and the FY2025 annual result came in at $2.2 million, up 48.37% from the prior year.
• Depreciation & Amortization (CF) grew to $631000.0 in Q1 2026 per IMDX's latest filing, from $590000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $631000.0 in Q1 2026 and troughed at $287000.0 in Q1 2022.
• A 5-year average of $434470.6 and a median of $404000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) soared 137.19% in 2022, then slumped 30.44% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $400000.0 in 2022, then retreated by 22.25% to $311000.0 in 2023, then jumped by 73.95% to $541000.0 in 2024, then climbed by 9.06% to $590000.0 in 2025, then gained by 6.95% to $631000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $631000.0, $590000.0, and $584000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.